» Articles » PMID: 16182986

Emergency Management of Agitation in Schizophrenia

Overview
Journal Am J Emerg Med
Specialty Emergency Medicine
Date 2005 Sep 27
PMID 16182986
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Schizophrenia is a common psychiatric condition, affecting approximately 1% of the population. Acute emergent presentations often include hallucinations, delusions, thought, and speech disorders. Agitation is common among emergency patients with schizophrenia. Decisional capacity should be assessed in all patients. Reversible causes of agitation should be ruled out, including infection, metabolic disorders, endocrine disorders, trauma, pain, noncompliance, toxicological disorders, and structural brain abnormalities. Agitation may be managed acutely using a combination of pharmacological agents and nonpharmacological interventions. Effective pharmacological agents include several classes of antipsychotic agents and benzodiazepines. Potential life-threatening complications of pharmacological therapy should be anticipated, which may include neuroleptic malignant syndrome (NMS), prolonged QT syndrome, and respiratory depression. Nonpharmacological interventions may include a quiet environment, physical restraints, and behavioral interventions. Disposition decisions should be made based on the etiology of agitation, effective management, decisional capacity, and presence of suicidal or homicidal intentions. Many patients who have required nonpharmacological or pharmacological management of agitation require inpatient psychiatric treatment, either voluntarily or involuntarily. Psychiatric consultation should be sought for patients with schizophrenia and uncertain disposition determinations, or those requiring other complex management decisions.

Citing Articles

Neurofeedback technique for treating male schizophrenia patients with impulsive behavior: a randomized controlled study.

Li Z, Ren H, Tian Y, Zhou J, Chen W, OuYang G Front Psychiatry. 2024; 15:1472671.

PMID: 39435128 PMC: 11491364. DOI: 10.3389/fpsyt.2024.1472671.


Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis.

Guarro Carreras M, Jimenez Suarez L, Lago Garcia L, Montes Reula L, Neyra Del Rosario A, Rodriguez Batista F Drugs Context. 2024; 13.

PMID: 39131604 PMC: 11313206. DOI: 10.7573/dic.2024-4-4.


Critical Issues in the Management of Agitation, Aggression, and End-of-Life in Delusional Disorder: A Mini-Review.

Gonzalez-Rodriguez A, Seeman M, Roman E, Natividad M, Pages C, Ghigliazza C Healthcare (Basel). 2023; 11(4).

PMID: 36832992 PMC: 9956049. DOI: 10.3390/healthcare11040458.


Psychometric Characteristics and Sociodemographic Adaptation of the Corrigan Agitated Behavior Scale in Patients With Severe Mental Disorders.

Garrote-Camara M, Santolalla-Arnedo I, Ruiz de Vinaspre-Hernandez R, Gea-Caballero V, Sufrate-Sorzano T, Pozo-Herce P Front Psychol. 2021; 12:779277.

PMID: 34955998 PMC: 8693627. DOI: 10.3389/fpsyg.2021.779277.


The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.

Pompili M, Ducci G, Galluzzo A, Rosso G, Palumbo C, de Berardis D Int J Environ Res Public Health. 2021; 18(8).

PMID: 33924111 PMC: 8074323. DOI: 10.3390/ijerph18084368.